News

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

Although shown to have no connection to autism in multiple studies, the mercury-based agent will no longer be included in multidose influenza shots.

Holden describes the importance of including SLD in global health policy frameworks and how a side event at the 78th WHA sought to address current gaps.

A new analysis found a 0.78% prevalence of CSU in US adults, exceeding earlier estimates, and revealed significant mental, physical, and work-related burdens.

A review of data from an ongoing phase 3 trial indicates the potential for a generalized, prespecified fitusiran treatment for hemophilia A and B.

RSV hospitalizations in older adults lead to worse health outcomes and increased cardiovascular risks, highlighting the need for vaccination and monitoring.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Sanyal describes the growing burden of SLD and its connection to other major chronic diseases, underscoring the need for better recognition and prevention efforts.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

Post-COVID CT guidance favors low-dose imaging, clear terms, and precise timing.

Positive topline results showed obefazimod met its primary endpoint for clinical remission at week 8 in the 50 mg dose cohort in ABECT-1 and ABECT-2.

In children with mild immediate or delayed reactions, direct drug provocation testing may eliminate the need for painful skin tests, according to new data from Türkiye.

This episode of Lungcast features a discussion on the connection between diet, gut microbiome and lung health.

Kuter describes several studies investigating aspects of rilzabrutinib which were presented at the ISTH 2025 Congress.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Study finds monthly HAE attacks dropped from 54% to 9.8% after 3 years of lanadelumab, with improved quality of life and reduced severity.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

Study findings showed IBS patients with self-perceived gluten sensitivity reacted similarly to gluten, wheat, and sham challenges.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

This interview with Saakshi Khattri, MD, highlights recent findings on deucravacitinib as an oral therapy for patients living with psoriatic arthritis (PsA).

Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.

A new study showed that cashew-induced anaphylaxis mostly affects children under 5 years, often from tiny amounts that are under a teaspoon.

In CKD patients with COVID-19, prior vaccination significantly reduced risks of major adverse kidney events and mortality, especially with ≥ 3 doses.